Success Metrics

Clinical Success Rate
28.6%

Based on 2 completed trials

Completion Rate
29%(2/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
5(71%)

Phase Distribution

Ph phase_1
6
86%
Ph phase_2
1
14%

Phase Distribution

6

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
6(85.7%)
Phase 2Efficacy & side effects
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

28.6%

2 of 7 finished

Non-Completion Rate

71.4%

5 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(2)
Terminated(5)

Detailed Status

Terminated5
Completed2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
28.6%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (85.7%)
Phase 21 (14.3%)

Trials by Status

terminated571%
completed229%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_1

AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors

NCT00372736
completedphase_1

AEG35156 and Docetaxel in Treating Patients With Solid Tumors

NCT00357747
terminatedphase_2

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

NCT01018069
terminatedphase_1

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

NCT00558545
terminatedphase_1

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

NCT00557596
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00372736Phase 1

AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors

Completed
NCT00357747Phase 1

AEG35156 and Docetaxel in Treating Patients With Solid Tumors

Completed
NCT01018069Phase 2

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Terminated
NCT00558545Phase 1

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

Terminated
NCT00557596Phase 1

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

Terminated
NCT00558922Phase 1

A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer

Terminated
NCT00385775Phase 1

Study of XIAP Antisense for Advanced Cancers

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7